

Stanford



Karen Chao

Clinical Assistant Professor, Pediatrics - Hematology & Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Children's Health**

1100 Van Ness Ave 7th Fl

San Francisco, CA 94109

Tel (844) 733-2762

Fax (650) 628-2270

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Xitlalli Jimenez - Administrative Assistant

Email xitlalli@stanford.edu

Tel 6507235535

Bio

CLINICAL FOCUS

- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Pediatrics - Hematology & Oncology
- Member, Stanford Cancer Institute

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Pediatric Hematology Oncology (2022 - present)

PROFESSIONAL EDUCATION

- MS, Medical College of Wisconsin, Clinical and Translational Science (2022)
- Fellowship: Medical College of Wisconsin Hematology/Oncology Fellowship Program (2022) WI
- Board Certification: Pediatrics, American Board of Pediatrics (2019)
- Residency: Medical College of Wisconsin Dept of Pediatrics (2019) WI
- Medical Education: University of Cincinnati College of Medicine (2012) OH

Publications

PUBLICATIONS

- **Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.** *Molecular therapy : the journal of the American Society of Gene Therapy*
Pasupuleti, S. K., Chao, K., Ramdas, B., Kanumuri, R., Palam, L. R., Liu, S., Wan, J., Annesley, C., Loh, M. L., Stieglitz, E., Burke, M. J., Kapur, R.
2023
- **Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TAFL consortium** *PEDIATRIC BLOOD & CANCER*
Schafer, E. S., Chao, K., Stevens, A. M., Jo, E., Hilsenbeck, S. G., Gossai, N. P., Doan, A., Colace, S. I., Guinipero, T., Otterson, D., Kaplan, J. A., Hinson, A., Pommert, et al

2022; 69 (10)

- **Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.**

Vandris, P., Chao, K., Baggott, C., Phillips, C. L., Qayed, M., Rossoff, J., Lim, S., Winestone, L. E., Stefanski, H. E., Talano, J. M., Margossian, S., Verneris, M. R., Myers, et al

LIPPINCOTT WILLIAMS & WILKINS.2022